Cart
sales@molnova.com
EAI001
CAS No. 892772-75-7
EAI001( —— )
Catalog No. M35525 CAS No. 892772-75-7
EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.EAI001 can be used in cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 48 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 164 | In Stock |
|
| 50MG | 273 | In Stock |
|
| 100MG | 430 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEAI001
-
NoteResearch use only, not for human use.
-
Brief DescriptionEAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.EAI001 can be used in cancer research.
-
DescriptionEAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer.
-
In VitroEAI001 (50 μM) binds to EGFR T790M/C797S/V948R that lies deep inside the EGFR towards the ATP binding site and C-helix. EAI001 showed inhibitory activity due to hydrophobic interaction with amino acid Ile759, Leu747, Leu788, Leu777 and Met766.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number892772-75-7
-
Formula Weight349.41
-
Molecular FormulaC19H15N3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (286.20 mM; Ultrasonic )
-
SMILESO=C(Nc1nccs1)C(N1Cc2ccccc2C1=O)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Maity S, et, al. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol Rep. 2020 Aug;72(4):799-813.?
molnova catalog
related products
-
Intetumumab
Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.
-
RO 46-8443
RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition.
-
Anlotinib
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
